Concenter BioPharma Ltd.

Our Story

Concenter BioPharma Ltd. (subsidiary of Silkim Pharma Ltd.) – Company Profile: Professor Chevion and co-inventors developed a family of non-steroidal chemical complexes, made of components approved for clinical use - this is our foundational science. These New Chemical Entities constitute a protected PLATFORM of DRUGS, with proven efficacy and complete safety, for treatments of multiple indications. The PLATFORM members show 3 synergistic Mechanisms of Action, extensively tested in animal models of human diseases (and anecdotal human cases). We are expecting IND approval from FDA leading to monetization events within 24 months and are currently raising $$$ to advance the development of our chosen drug for treating and preventing TYPE 2 DIABETES (leveraging FDA "shortcut routes") and enhancing our IP. Our PLATFORM of Drugs is unique: * Small molecule, non-steroidal * From a natural source of GRAS (micro)organism * Infiltrates into tissues and cells; Crosses the BBB * Can be delivered per os, topically and systemically as well as other innovative routes * The drug is 100x more efficacious than its components * Our PLATFORM enables accelerated expansion from one proven product to another without having to rediscover and re-create an underlying specific technology for each product.